{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T14:51:05Z","timestamp":1770475865253,"version":"3.49.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Bortezomib, a potent and reversible proteasome inhibitor, affects the myeloma cell and its microenvironment, resulting in down-regulation of growth and survival signaling pathways and durable responses in patients with relapsed and refractory myeloma. Potential associations between baseline parameters and outcomes with bortezomib were explored in 202 patients who received bortezomib 1.3 mg\/m2 twice weekly for 2 weeks every 3 weeks for up to 8 cycles in a phase 2 trial. Using European Group for Blood and Marrow Transplantation criteria, the response rate (complete or partial response) to bortezomib alone was 27% and was not associated with sex, race, performance status, isotype, chromosome 13 deletion, number or type of previous therapies, or concentration of hemoglobin or \u03b22-microglobulin. By multivariate analysis, factors associated with lower response were being age 65 or older versus younger than 65 (19% vs 32%; P &amp;lt; .05) and plasma-cell infiltration in bone marrow greater than 50% versus 50% or less (20% vs 35%; P &amp;lt; .05). Factors that may be indicative of tumor burden (bone marrow plasma-cell infiltration greater than 50%, hypoalbuminemia, thrombocytopenia) were predictive of overall survival. Chromosome 13 deletion and elevated \u03b22-microglobulin, generally considered poor prognostic factors, were not predictive of poor outcome with bortezomib in this study.<\/jats:p>","DOI":"10.1182\/blood-2005-02-0691","type":"journal-article","created":{"date-parts":[[2005,7,14]],"date-time":"2005-07-14T20:24:22Z","timestamp":1121372662000},"page":"2977-2981","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":93,"title":["Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma"],"prefix":"10.1182","volume":"106","author":[{"given":"Paul Gerard Guy","family":"Richardson","sequence":"first","affiliation":[{"name":"From the Dana-Farber Cancer Institute, Boston, MA; University of Arkansas for Medical Sciences, Little Rock, AR; Cedars-Sinai Medical Center, Los Angeles, CA; Northwestern Memorial Hospital, Chicago, IL; St Vincent's Comprehensive Cancer Center, New York, NY; Alta Bates Cancer Center, Berkeley, CA; Mayo Clinic, Rochester, MN; and Millenium Pharmaceuticals, Inc., Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Barlogie","sequence":"additional","affiliation":[{"name":"From the Dana-Farber Cancer Institute, Boston, MA; University of Arkansas for Medical Sciences, Little Rock, AR; Cedars-Sinai Medical Center, Los Angeles, CA; Northwestern Memorial Hospital, Chicago, IL; St Vincent's Comprehensive Cancer Center, New York, NY; Alta Bates Cancer Center, Berkeley, CA; Mayo Clinic, Rochester, MN; and Millenium Pharmaceuticals, Inc., Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Berenson","sequence":"additional","affiliation":[{"name":"From the Dana-Farber Cancer Institute, Boston, MA; University of Arkansas for Medical Sciences, Little Rock, AR; Cedars-Sinai Medical Center, Los Angeles, CA; Northwestern Memorial Hospital, Chicago, IL; St Vincent's Comprehensive Cancer Center, New York, NY; Alta Bates Cancer Center, Berkeley, CA; Mayo Clinic, Rochester, MN; and Millenium Pharmaceuticals, Inc., Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema","family":"Singhal","sequence":"additional","affiliation":[{"name":"From the Dana-Farber Cancer Institute, Boston, MA; University of Arkansas for Medical Sciences, Little Rock, AR; Cedars-Sinai Medical Center, Los Angeles, CA; Northwestern Memorial Hospital, Chicago, IL; St Vincent's Comprehensive Cancer Center, New York, NY; Alta Bates Cancer Center, Berkeley, CA; Mayo Clinic, Rochester, MN; and Millenium Pharmaceuticals, Inc., Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[{"name":"From the Dana-Farber Cancer Institute, Boston, MA; University of Arkansas for Medical Sciences, Little Rock, AR; Cedars-Sinai Medical Center, Los Angeles, CA; Northwestern Memorial Hospital, Chicago, IL; St Vincent's Comprehensive Cancer Center, New York, NY; Alta Bates Cancer Center, Berkeley, CA; Mayo Clinic, Rochester, MN; and Millenium Pharmaceuticals, Inc., Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Irwin","sequence":"additional","affiliation":[{"name":"From the Dana-Farber Cancer Institute, Boston, MA; University of Arkansas for Medical Sciences, Little Rock, AR; Cedars-Sinai Medical Center, Los Angeles, CA; Northwestern Memorial Hospital, Chicago, IL; St Vincent's Comprehensive Cancer Center, New York, NY; Alta Bates Cancer Center, Berkeley, CA; Mayo Clinic, Rochester, MN; and Millenium Pharmaceuticals, Inc., Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"From the Dana-Farber Cancer Institute, Boston, MA; University of Arkansas for Medical Sciences, Little Rock, AR; Cedars-Sinai Medical Center, Los Angeles, CA; Northwestern Memorial Hospital, Chicago, IL; St Vincent's Comprehensive Cancer Center, New York, NY; Alta Bates Cancer Center, Berkeley, CA; Mayo Clinic, Rochester, MN; and Millenium Pharmaceuticals, Inc., Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teru","family":"Hideshima","sequence":"additional","affiliation":[{"name":"From the Dana-Farber Cancer Institute, Boston, MA; University of Arkansas for Medical Sciences, Little Rock, AR; Cedars-Sinai Medical Center, Los Angeles, CA; Northwestern Memorial Hospital, Chicago, IL; St Vincent's Comprehensive Cancer Center, New York, NY; Alta Bates Cancer Center, Berkeley, CA; Mayo Clinic, Rochester, MN; and Millenium Pharmaceuticals, Inc., Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugh","family":"Xiao","sequence":"additional","affiliation":[{"name":"From the Dana-Farber Cancer Institute, Boston, MA; University of Arkansas for Medical Sciences, Little Rock, AR; Cedars-Sinai Medical Center, Los Angeles, CA; Northwestern Memorial Hospital, Chicago, IL; St Vincent's Comprehensive Cancer Center, New York, NY; Alta Bates Cancer Center, Berkeley, CA; Mayo Clinic, Rochester, MN; and Millenium Pharmaceuticals, Inc., Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dixie","family":"Esseltine","sequence":"additional","affiliation":[{"name":"From the Dana-Farber Cancer Institute, Boston, MA; University of Arkansas for Medical Sciences, Little Rock, AR; Cedars-Sinai Medical Center, Los Angeles, CA; Northwestern Memorial Hospital, Chicago, IL; St Vincent's Comprehensive Cancer Center, New York, NY; Alta Bates Cancer Center, Berkeley, CA; Mayo Clinic, Rochester, MN; and Millenium Pharmaceuticals, Inc., Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Schenkein","sequence":"additional","affiliation":[{"name":"From the Dana-Farber Cancer Institute, Boston, MA; University of Arkansas for Medical Sciences, Little Rock, AR; Cedars-Sinai Medical Center, Los Angeles, CA; Northwestern Memorial Hospital, Chicago, IL; St Vincent's Comprehensive Cancer Center, New York, NY; Alta Bates Cancer Center, Berkeley, CA; Mayo Clinic, Rochester, MN; and Millenium Pharmaceuticals, Inc., Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"From the Dana-Farber Cancer Institute, Boston, MA; University of Arkansas for Medical Sciences, Little Rock, AR; Cedars-Sinai Medical Center, Los Angeles, CA; Northwestern Memorial Hospital, Chicago, IL; St Vincent's Comprehensive Cancer Center, New York, NY; Alta Bates Cancer Center, Berkeley, CA; Mayo Clinic, Rochester, MN; and Millenium Pharmaceuticals, Inc., Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the SUMMIT Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021215433637600_REF1","doi-asserted-by":"crossref","unstructured":"Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc.2003;78: 21-33.","DOI":"10.4065\/78.1.21"},{"key":"2020021215433637600_REF2","doi-asserted-by":"crossref","unstructured":"Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc.2004;79: 867-874.","DOI":"10.4065\/79.7.867"},{"key":"2020021215433637600_REF3","doi-asserted-by":"crossref","unstructured":"Desikan R, Barlogie B, Sawyer J, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood.2000;95: 4008-4010.","DOI":"10.1182\/blood.V95.12.4008"},{"key":"2020021215433637600_REF4","doi-asserted-by":"crossref","unstructured":"Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood.1993;81: 3382-3387.","DOI":"10.1182\/blood.V81.12.3382.3382"},{"key":"2020021215433637600_REF5","doi-asserted-by":"crossref","unstructured":"Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood.2001;97: 1566-1571.","DOI":"10.1182\/blood.V97.6.1566"},{"key":"2020021215433637600_REF6","unstructured":"Fonseca R, Harrington D, Oken MM, et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an Eastern Cooperative Oncology Group study. Cancer Res.2002;62: 715-720."},{"key":"2020021215433637600_REF7","unstructured":"Rajkumar SV, Mesa RA, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res.2002;8: 2210-2216."},{"key":"2020021215433637600_REF8","unstructured":"Greipp PR, Kumar S, Blood EA, et al. A simple classification to identify poor-risk untreated myeloma [abstract]. Blood.2002;100: 598."},{"key":"2020021215433637600_REF9","doi-asserted-by":"crossref","unstructured":"Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley JJ. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol.2003;122: 441-450.","DOI":"10.1046\/j.1365-2141.2003.04456.x"},{"key":"2020021215433637600_REF10","unstructured":"Menon H, Kumar K, Ganessan K, et al. Autologous stem cell transplantation (ASCT) in multiple myeloma (MM): analysis of prognostic factors [abstract]. Proc Am Soc Clin Oncol.2003;22: 608."},{"key":"2020021215433637600_REF11","doi-asserted-by":"crossref","unstructured":"Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N Engl J Med.1996;335: 91-97.","DOI":"10.1056\/NEJM199607113350204"},{"key":"2020021215433637600_REF12","doi-asserted-by":"crossref","unstructured":"Cavo M, Galieni P, Zuffa E, Baccarani M, Gobbi M, Tura S. Prognostic variables and clinical staging in multiple myeloma. Blood.1989;74: 1774-1780.","DOI":"10.1182\/blood.V74.5.1774.1774"},{"key":"2020021215433637600_REF13","doi-asserted-by":"crossref","unstructured":"Mileshkin L, Biagi JJ, Mitchell P, et al. Multicenter phase 2 trial of thalidomide in relapsed\/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood.2003;102: 69-77.","DOI":"10.1182\/blood-2002-09-2846"},{"key":"2020021215433637600_REF14","doi-asserted-by":"crossref","unstructured":"Zangari M, Barlogie B, Thertulien R, et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma.2003;4: 32-35.","DOI":"10.3816\/CLM.2003.n.011"},{"key":"2020021215433637600_REF15","doi-asserted-by":"crossref","unstructured":"Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood.2001;98: 492-494.","DOI":"10.1182\/blood.V98.2.492"},{"key":"2020021215433637600_REF16","unstructured":"Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res.1999;59: 2615-2622."},{"key":"2020021215433637600_REF17","doi-asserted-by":"crossref","unstructured":"Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med.2003;348: 2609-2617.","DOI":"10.1056\/NEJMoa030288"},{"key":"2020021215433637600_REF18","unstructured":"Richardson PG, Barlogie B, Berenson J, et al. Survival, duration of response, and time to progression with bortezomib in patients with relapsed and refractory myeloma: an update [abstract]. Hematol J.2004;5(suppl 2): S128."},{"key":"2020021215433637600_REF19","unstructured":"Greipp PR, San Miguel JF, Durie BGM, et al. A new international staging system (ISS) for multiple myeloma (MM) from the International Working Group [abstract]. Blood.2003;102: 190."},{"key":"2020021215433637600_REF20","doi-asserted-by":"crossref","unstructured":"Blade\u0301 J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT: European Group for Blood and Marrow Transplant. Br J Haematol.1998;102: 1115-1123.","DOI":"10.1046\/j.1365-2141.1998.00930.x"},{"key":"2020021215433637600_REF21","doi-asserted-by":"crossref","unstructured":"Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethazone for relapsed multiple myeloma. N Engl J Med.2005;352: 2487-2498.","DOI":"10.1056\/NEJMoa043445"},{"key":"2020021215433637600_REF22","doi-asserted-by":"crossref","unstructured":"Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res.2004;64: 1546-1558.","DOI":"10.1158\/0008-5472.CAN-03-2876"},{"key":"2020021215433637600_REF23","unstructured":"Richardson PG, Barlogie B, Berenson JR, et al. Prognostic factors associated with response in patients with relapsed and refractory multiple myeloma (MM) treated with bortezomib [abstract]. Proc Am Soc Clin Oncol.2003;22: 581."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/9\/2977\/1636173\/zh802105002977.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/9\/2977\/1636173\/zh802105002977.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T15:43:52Z","timestamp":1581522232000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/106\/9\/2977\/21938\/Clinical-factors-predictive-of-outcome-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,1]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,11,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-02-0691","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,1]]}}}